THE
CANNABIS SCIENCE INAUGURAL BLACK-TIE AWARDS GALA FINAL
PLANNING
UNDERWAY; RECOGNIZING MAJOR
INDUSTRY
ACCOMPLISHMENTS,
KILLING CANCER, AND AWARDING UNPRECEDENTED
SHAREHOLDER
LOYALTY
IRVINE,
CA -- November 21, 2018 -- InvestorsHub NewsWire -- Cannabis
Science, Inc. (USOTC:
CBIS), a U.S. company specializing in the development of
cannabinoid-based medicines, is pleased to announce that the
inaugural CBIS Black-tie Gala has morphed into the Cannabis Science
Awards Black-Tie Gala Ceremony that it should be. Still slated for
Los Angeles, California, a possible pre-event mixer at one of the
venues later this year, and realistically, the main Black-Tie
Dinner Awards Gala will be slated for early next year. The Company
is excited to commit to announcing the final list of events,
venues, dates and times before the end of this year.
The
Company has potential arrangements and offers now from
a number
of different types of
venues, caters, performers, and event public relations
professionals including celebrities to help promote the event. The
target goal is to raise the awareness and understanding of Cannabis
Science and the appropriate clinical research to effect the change
we want to see in clinical drug development programs for
cannabinoids targeting critical ailments and palliative
care.
Through
its Black-Tie Awards Gala, Cannabis Science intends to celebrate
the Company's accomplishments in the medical-cannabis industry,
along with those who have been instrumental in the Company's
achievements, namely its many partners, individuals and companies,
its shareholders and key industry individuals are slated receive
the Awards. The program for the Cannabis Science Black-tie Awards
Gala will include cannabis treatment success stories from patients
and physicians, live entertainment, fundraising auctions, and
updates from the Company about new drug developments and future
expansion plans. The Black-Tie Awards Gala will also showcase
Cannabis Science's new Pharmacies, and Mr. Raymond C. Dabney
intends to Award his loyalty shareholder gifts to shareholders at
this event.
The
Company is looking forward to creating a full day of events
including conferences, workshops, mixers, and all cumulating to the
Black-Tie Awards Dinner. This long-awaited event will be jointly
hosted by Cannabis Science and some of its partners and will raise
awareness and funds for increased proper clinical medical cannabis
research to develop medicines to treat critical ailments such as
various cancers, chronic pain, post-traumatic stress disorder
(PTSD), neurological disorders, and many more.
"2018 has
been an exciting year of major accomplishments for Cannabis Science
and we have put in place a number of initiatives that we expect to
contribute to our long-term growth and profitability," stated Mr.
Raymond C. Dabney, Cannabis Science Inc., President &
CEO, CoFounder.
"We also experienced a number of challenges and the biggest of
course, was having to overcome the loss of our Chief Medical
Officer, Dr. Allen Herman, who died after a brief illness earlier
this year. With Allen's legacy in mind, we are moving ahead very
strong, and I believe we have the right team in place to propel our
Company forward for decades to come. The Black-tie Gala Awards
Celebration will provide an opportunity to reflect on our
accomplishments and thank those who have contributed in so many
different and important ways."
Reflecting
back through previous CBIS
Black-Tie Gala news releases;
"The
Cannabis Science Gala will be open to the Company's shareholders
and stakeholders, and will include strategic partners, researchers,
celebrities, and other interested parties. "The Cannabis Science
Gala is -- most importantly -- an event to accumulate support for
the eradication of critical ailments and improved palliative care
in mainstream and distressed demographics. To show our gratitude to
our shareholders, I will present the loyalty stock gifts at the
Gala. The gala will also provide the Company with the opportunity
to gather with leaders in the field of cannabinoid research to
share information and ideas on critical ailments being addressed by
our research," stated Mr. Raymond C. Dabney, Cannabis Science's
President, Chief Executive Officer, and Cofounder." 11 August
2017
"The 2017
Gala Event is for everyone! Our work is always targeted to those
suffering from the many illnesses that may effectively be treated
using cannabinoids. We are moving rapidly to serve these patients
as quickly as possible. This Gala Event will give us a platform to
reach a great number of people in need. We have chosen Beverly
Hills, CA as the host city for the 2017 Gala and we will shortly
announce the dates. I am excited to finally make the loyalty
shareholder gift announcements at the 2017 Gala and release some
new and exciting venture partnership opportunities," stated
Cannabis Science Inc., President & CEO, Co-Founder, Mr. Raymond
C. Dabney. 7 May 2017
"We have
had this idea of creating a spectacular Gala event for over a year
now," said Director, President, CEO & Co-Founder Raymond C.
Dabney, "This is certainly a Fundraiser for cannabinoid research
targeting critical ailments, patient and doctor testimonials and
awards, sponsorship packages, great food and entertainment,
celebrity interests and accomplishments in the industry, and new
partnership announcements are all on the agenda. We are very
excited to see our hard work coming to fruition. Our shareholders
will be able to tangibly see the work we have been doing, help us
raise funds and awareness for cannabis treatment research, and of
course receive their loyalty stock gifts. This is something we feel
has long been overdue, and we are going all out to make this an
incredible event. I am pleased that we are making progress to get
this promised Loyalty gift to our shareholders; we here at Cannabis
Science understand this has been a long process and would like to
extend a thank you to shareholders for the patience they have shown
as we hope to soon reward them all," stated, CEO and Co-Founder Mr.
Raymond C. Dabney. 25 April 2017
"Cannabis
Science will host a black tie, red carpet Gala event in Los
Angeles, entitled "Cannabis Kills Cancer." Celebrities, patients,
scientists, physicians, and shareholders are expected to attend.
The event is intended to raise funds for cannabis-focused cannabis
research. Mr. Dabney will reveal his loyalty gift share program at
the Gala event while highlighting historical breakthroughs the
Company has achieved during its first 7 years of operations in the
cannabis industry. This Gala Event will set the stage for the
Company to raise "Millions of Dollars to Continue the Fight" by
expanding its treatment base targeting critical ailments. The funds
raised will go to expand current clinical studies the
Company has under way targeting cancer, HIV/AIDS, sleep disorders,
pain management, PTSD, autism, and many more critical ailments." 20
July 2016
"The
Cannabis Science Gala will be open to the Company's shareholders
and stakeholders, and will include strategic partners, researchers,
celebrities, and other interested parties. "The Cannabis Science
Gala is -- most importantly -- an event to accumulate support for
the eradication of critical ailments and improved palliative care
in mainstream and distressed demographics. To show our gratitude to
our shareholders, I will present the loyalty stock gifts at the
Gala. The gala will also provide the Company with the opportunity
to gather with leaders in the field of cannabinoid research to
share information and ideas on critical ailments being addressed by
our research," stated Mr. Raymond C. Dabney, Cannabis Science's
President, Chief Executive Officer, and Cofounder." 11 August
2017
"The 2017
Gala Event is for everyone! Our work is always targeted to those
suffering from the many illnesses that may effectively be treated
using cannabinoids. We are moving rapidly to serve these patients
as quickly as possible. This Gala Event will give us a platform to
reach a great number of people in need. We have chosen Beverly
Hills, CA as the host city for the 2017 Gala and we will shortly
announce the dates. I am excited to finally make the loyalty
shareholder gift announcements at the 2017 Gala and release some
new and exciting venture partnership opportunities," stated
Cannabis Science Inc., President & CEO, Co-Founder, Mr. Raymond
C. Dabney. 7 May 2017
"We have
had this idea of creating a spectacular Gala event for over a year
now," said Director, President, CEO & Co-Founder Raymond C.
Dabney, "This is certainly a Fundraiser for cannabinoid research
targeting critical ailments, patient and doctor testimonials and
awards, sponsorship packages, great food and entertainment,
celebrity interests and accomplishments in the industry, and new
partnership announcements are all on the agenda. We are very
excited to see our hard work coming to fruition. Our shareholders
will be able to tangibly see the work we have been doing, help us
raise funds and awareness for cannabis treatment research, and of
course receive their loyalty stock gifts. This is something we feel
has long been overdue, and we are going all out to make this an
incredible event. I am pleased that we are making progress to get
this promised Loyalty gift to our shareholders; we here at Cannabis
Science understand this has been a long process and would like to
extend a thank you to shareholders for the patience they have shown
as we hope to soon reward them all," stated, CEO and Co-Founder Mr.
Raymond C. Dabney. 25 April 2017
"Cannabis
Science will host a black tie, red carpet Gala event in Los
Angeles, entitled "Cannabis Kills Cancer." Celebrities, patients,
scientists, physicians, and shareholders are expected to attend.
The event is intended to raise funds for cannabis-focused cannabis
research. Mr. Dabney will reveal his loyalty gift share program at
the Gala event while highlighting historical breakthroughs the
Company has achieved during its first 7 years of operations in the
cannabis industry. This Gala Event will set the stage for the
Company to raise "Millions of Dollars to Continue the Fight" by
expanding its treatment base targeting critical ailments. The funds
raised will go to expand current clinical studies the Company has
under way targeting cancer, HIV/AIDS, sleep disorders, pain
management, PTSD, autism, and many more critical ailments." 20 July
2016
Cannabis
Science's major initiatives and accomplishments in 2018
include:
1.
Expansion of the Cannabis Science Global Consortium and Drug
Development
Progress In
2018, Cannabis Science continues to expand its Global Consortium
through new and expanded relationships with leading research
institutions in the United States and globally. The Company is
linking alternative drug research, education, and job creation with
universities, foundations, corporations, and key individuals all
looking to create a robust environment to share research, ideas,
and other relevant information as a powerful influential team. The
Cannabis Science Global Consortium is implementing cutting-edge
research programs to develop new medicines and delivery mechanisms
from bench-tobedside
in
demographics with great medical needs, or with little or no basic
resources, and other key embattled demographic areas.
Cannabis
Science's primary objective is to research and develop U.S. Food
and Drug Administration (FDA)-approved, cannabinoid-based medicine
to fight a number of
targeted
critical ailments, including various Cancers, Neurological
Conditions, PTSD, Sleep Deprivation, Chronic Pain, HIV/AIDS,
Autism, Parkinson's Disease, Epilepsy, Chronic Obstructive
Pulmonary Disease (COPD), and others. CBIS and its collaborators
are well underway on a number of
research
projects targeting Lung Cancer, Pancreatic Cancer, Chronic Pelvic
Pain, and Oro-bucco-lingual
Dyskinesias.
Cannabis
Science's current research forms part of a pipeline from research
to scientific publication that the Company is developing with its
research partners, and
demonstrates the
Company's strong commitment to science in its pharmaceutical
development program. Cannabis Science's funded research focuses on
the clinical applications of cannabinoids in cancer treatment and
pain management, and will expand in the following significant
directions: (a) investigate the effectiveness of cannabinoid
treatment in an increasing array of cancers, especially difficult
to treat cancers and those with high fatality rates, (b) develop
novel targeted delivery methods in the use of cannabinoids, and (c)
explore the mechanisms of action of cannabinoids in the management
of disease with advances in bioinformatics, computer science, and
pharmacology.
As a
result of the Company's research activities, Cannabis Science and
its collaborators have published two peer-reviewed research papers
in the cancer research journal,
Frontiers in Oncology:
Nanoparticle Drones to Target Lung Cancer with Radiosensitizers
and
Cannabinoids:
https://www.frontiersin.org/articles/10.3389/fonc.2017.00208/full
Enhancing the Therapeutic Efficacy of Cancer Treatment with
Cannabinoids:
https://www.frontiersin.org/articles/10.3389/fonc.2018.00114/full
2.
Cannabis Science's Economic Development Initiative Update
Cannabis
Science's Economic Development Initiative is well underway, and the
Company previously announced its first major project with Free
Spirit Organics Native American Corporation (FSO NAC) and the
Company's University partners for a comprehensive educational,
economic, and property development program. With the Universities
at the helm, FSO NAC, Cannabis Science, and its University land
partners are poised to become among the country's leading
cannabinoid producers. The Company's educational partners provide
educational packages for the community in Law, Business,
Healthcare, and 37 other trade industries, as well as
entrepreneurial job creation programs.
The main
function of the University Partnerships is the responsibility and
complete oversight of the Company's Economic Development
Initiative. As an intricate part of each land package deal, the
implementing University Partners expect to provide full
scholarships and additionally-subsidized education packages to
members of the Native American community and any other challenged
individuals with the desire to grow with the initiative. Job
creation and most importantly on the job training.
Because
of the initial success of Cannabis Science's Economic Development
Initiative with FSO NAC, the Company is currently in discussions
with a number of
large
Native American Tribes, Universities, and private-sector
organizations who have expressed an interest in launching Cannabis
Science's Economic Development Initiative in several states,
including California, Nevada, Michigan, and New York.
3.
Opening of the Cannabis Science Pharmacies in California
Cannabis
Science successfully opened the first two Pharmacies in California.
The launching of the Pharmacies is an important part of the
Company's overall drug-development strategy. These Pharmacies
provide Cannabis Science with an important retail sales channel and
enable the Company to interact directly with those who will benefit
from its medicines Cannabis Science's patients.
The
Pharmacies showcase the Company's brand of high-quality cannabinoid
and cannabisbased
products
and accessories for patients, doctors, and the consuming public.
These products range from pills, creams, extracts, sprays,
tinctures, edibles, balms, patches, oils, raw products, and
merchandise. The Pharmacies also showcase other brands as well, for
patient continuity and familiarity.
4.
Acquisition of
Cannabia -
On March 14, 2018, Cannabis Science announced a new partnership
with Crown Baus
Capital
Corporation (OTC: CBCA) to distribute Cannabia
in
the United States and Canada. Crown Baus
Capital
acquired a 100% stake in Cannabia,
the world's first alcoholic, cannabis beer.
The
acquisition of Cannabia
and
Cannabis Science's distribution partnership with Crown
Baus
Capital
are strategically important to the Company's growth strategy, and
more acquisitions are planned to drive operational growth and
maximize profitability,
so
savings can be passed on to Cannabis Science's valued,
self-medicating patients and general public consumers.
Cannabia
sales
have been growing 15 to 25% per year, and beverage sales are
expected to increase substantially as Cannabis Science
introduces Cannabia
products
into the U.S. and Canadian markets. California alone is the world's
sixth-largest economy with a GDP of $2.5 trillion. This represents
a very large market opportunity for Cannabis Science, who will
distribute Cannabia
non-alcoholic
beverage lines through its Pharmacies. Cannabis Science's
President, CEO, and Co-founder, Mr. Raymond C. Dabney, is the
President, CEO, and Co-founder of Crown Baus
Capital.
5.
Launch of
iCannabinoid
and
iCannabinoid
Marketplace Websites Earlier
this year, Cannabis Science announced the Beta Launch of its
iCannabinoid
website,
a state-of-theart,
high technology social media and educational platform. The Company
expects iCannabinoid
to
quickly become the premier online platform for all things
cannabinoidrelated,
and will create a community of patients, advocates, doctors,
researchers, parents, lawyers, growers, journalists, government and
private-sector leaders, community organizers, and other interested
parties. To join in the Beta Launch of iCannabinoid,
please visit and register at
http://icannabinoid.com/.
iCannabinoid
is
designed to serve as an information center, resource hub, and
support group for those seeking alternative cannabinoid treatments
for various critical ailments such as cancer, arthritis,
Parkinson`s Disease, anxiety, Multiple Sclerosis, and more. This
new website is designed to be a conduit to provide timely and
relevant information for cannabis users to share with each other
24/7 online.
iCannabinoid's
My Health
Modules are a significant feature in iCannabinoid
that
allow Members to set up fully integrated personal health modules
for tracking health records and set goals. Easy access and editable
modules are provided for Members to create medication lists,
monitor dosage results, monitor heart rate and blood pressure,
check and track sleep patterns, monitor pain influxes, along with
the flexibility to create unique health tracking modules for
Members' personal needs. Members can track personal health goals
and milestones, as well as many other items relating to specific
personal health maintenance.
To ensure
privacy, iCannabinoid's
My Health
Section will only be accessible by the individual Member. Members
will have the option to share approved modules with other Members,
as well as see other Members' approved modules that have also been
shared.
iCannabinoid
Members
will be able to track and share their personal experiences with
cannabinoid treatments through action groups, chat, blogs, photos,
and videos. These experiences will serve to educate and inspire
other Members, as well as allow Members to connect based on their
interests and profile information. Discussion groups can be created
to connect with people of the same interests, potentially allowing
patients to schedule consultations with doctors in the future, as
well as sign up for future clinical trials for novel cannabinoid
therapies. iCannabinoid
will
provide opportunities to enlighten medical practitioners on all
aspects of cannabinoid therapies and the endocannabinoid
system
and allow them to
directly interact with and help patients. Furthermore, this
platform will empower patients to educate themselves through
sharing information about the potential benefits of using
cannabinoids as a complementary therapy to lessen side effects such
as nausea, insomnia, and anxiety. Advocates of medical cannabinoids
can also demonstrate their support for legalization by signing up
to advocate for common sense medical cannabis
legislation.
In
addition to iCannabinoid,
the Beta Launch of iCannabinoid
Marketplace was
recently announced by Crown Baus
Capital.
iCannabinoid
Marketplace is an
online live-negotiating platform that enables buyers and sellers to
negotiate, in real time, for the procurement of equipment and
supplies related to the cultivation, extraction, manufacturing, and
packaging of medical-cannabis equipment and supplies. The
underlying technology for iCannabinoid
and
iCannabinoid
Marketplace is Live
Media Marketplace, which is owned by Crown Baus
Capital
Corporation. For more information and to register to buy or sell
products, visit
www.marketplace.icannabinoid.com.
The
iCannabinoid
Marketplace uses
real-time, streaming technology to provide users with the ability
to instantly find and negotiate with buyers and sellers of medical
marijuana equipment and supplies worldwide. The Marketplace will be
available 24-hours a day, and will provide real-time, live
inventory updating capabilities, as well as an instant private
negotiating environment. iCannabinoid
Marketplace will
provide a secure platform, and all buyers and sellers will be able
to negotiate live, via this platform, choosing currencies from
around the world. The system will provide private, one-on-one, and
one-to-many negotiations while dynamically loading and matching
inventory changes and instantly updating new opportunities.
iCannabinoid
Marketplace will also
help registered users reach optimum market prices for equipment and
supplies, without compromising the seller's proprietary pricing
information or identity, if they so choose.
6.
Cannabis Science's Africa Initiative Through its Cannabis
Science Global Consortium, the Company is currently developing
initiatives in Namibia, South Africa, and Nigeria, and is in the
early stages of identifying opportunities in a number of
other
African countries. The scope of Cannabis Science's current research
in Africa includes investigating the use of cannabinoids to treat
chronic pain disorders, cancers, neurological conditions, PTSD,
HIV/AIDS, and other critical/chronic indications, as well as
on oro-bucco-lingual
dyskinesias, oxidative stress, and psychosis. This initial work
program will allow Cannabis Science to do its ground work, identify
cultivation/grow locations, and expand the
Company's
drug development and economic development programs across the
African Continent. Products are being formulated and an initial
animal study is underway, with clinical trials planned for
2019.
About
Cannabis Science, Inc.
Cannabis
Science, Inc. takes advantage of its unique understanding of
metabolic processes to provide novel treatment approaches to
a number
of illnesses for which
current treatments and understanding remain
unsatisfactory. Cannabinoids have an extensive history dating back
thousands of years, and currently, there are a growing number of
peer-reviewed scientific publications that document the underlying
biochemical pathways that cannabinoids modulate. The Company works
with leading experts in drug development, medicinal
characterization, and clinical research to develop, produce, and
commercialize novel therapeutic approaches for the treatment for
illnesses caused by infections as well as for age-related illness.
Our initial focus is on cancers, HIV/AIDS, and neurological
conditions. The Company is proceeding with the research and
development of its proprietary drugs as a part of this initial
focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1,
respectively.
Forward-Looking
Statements
This
Press Release includes forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933 and Section
21E of the Securities Act of 1934. A statement containing words
such as "anticipate," "seek," intend," "believe," "estimate,"
"expect," "project," "plan," or similar phrases may be deemed
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. Some or
all
of the events or results
anticipated by these forward-looking statements may not occur.
Factors that could cause or contribute to such differences include
the future U.S. and global economies, the impact of competition,
and the Company's reliance on existing regulations regarding the
use and development of cannabis-based drugs. Cannabis Science,
Inc., does not undertake any duty nor does it intend to update the
results of these forward-looking statements. Safe Harbor Statement.
The Private Securities Litigation Reform Act of 1995 provides a
'safe harbor' for forward looking statements. Certain of the
statements contained herein, which are not historical facts are
forward looking statements with respect to events, the occurrence
of which involved risks and uncertainties. These forward-looking
statements may be impacted, either positively or negatively, by
various factors. Information concerning potential factors that
could affect the company is detailed from time to time in the
company's reports filed with the Securities and Exchange
Commission.
Contact
Information